Glowing dye could save voices in esophageal cancer surgery
NCT ID NCT07406815
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a dye called indocyanine green (ICG), given before surgery, can help surgeons see and protect the recurrent laryngeal nerve during esophageal cancer removal. About 144 adults with esophageal cancer will be randomly assigned to get the dye or standard surgery. The goal is to see if the dye lowers the chance of nerve injury, which can cause voice hoarseness and swallowing problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 144 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 18 and 75 years at the time of diagnosis (excluding 18 and 75); * Preoperative biopsy pathology confirming esophageal cancer; * Undergoing elective thoracoscopic esophageal cancer radical surgery with intraoperative anastomosis; * Tolerable heart, lung, liver, and kidney function for surgery; * Patients and their families are able to understand and willing to participate in this clinical study, and have signed an informed consent form. Exclusion Criteria: * Allergy to ICG or iodine; * History of neck or thoracic surgery; * Patients requiring emergency surgery; * Tumors involving adjacent organs necessitating combined organ resection; * Patients with tumor recurrence or distant metastasis; * Participation in or having participated in other clinical trials within 4 weeks prior to selection; * History of severe mental illness; * Pregnant or lactating women; * Patients with other conditions deemed unsuitable for participation by the investigator; * Intraoperative conversion to open thoracotomy. * Patients who, after assessment or intraoperative exploration, cannot undergo the planned surgery; * Patients who voluntarily withdraw from the study; * Patients with concomitant non-neoplastic conditions that prevent them from continuing with the study protocol; * Patients who, after enrollment in the study, are unable to complete it due to other reasons.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can a guided missile for chemo hit tumors harder and spare healthy tissue?
- Can a new drug shrink tumors that resist standard care?